PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form Complete if Known 10/542,602 (PCT/CA2004/000033) Application Number **INFORMATION DISCLOSURE** I.A. Filing Date January 19, 2004 STATEMENT BY APPLICANT First Named Inventor Stuart A. Berger Art Unit Not yet assigned (Use as many sheets as necessary) Examiner Name Not yet assigned Sheet of 2 10723-107 Attorney Docket Number

			U.S. PATENT	DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan
tnitiats *	Cite No.'	Number - Kind Code ² (if known)	MM-OD-YYYY	Caed Document	Passages or Relevant Figures Appear
		US-			
		US			
		US-			
	l	US-			
		US-			I

		FOREIGN PA	TENT DOCU	MENTS		
Examiner Initials*	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁸ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁰
					· · · · · · · · · · · · · · · · · · ·	

Examiner Signature	/Walter Webb/	Date Considered	12/20/2007

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include copy of this form with next communication to explicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspio.gogy or MPEP 901.04. Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under MPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03) Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

	Complete if Known
Application Number	10/542,602 (PCT/CA2004/000033)
I.A. Filing Date	January 19, 2004
First Named Inventor	Stuart A. Berger
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	10723-107

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/W.W.	1	YICHENG ZHANG and STUART A. BERGER, Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo, Cancer Chemother Pharmacol 2003 51(5):407-414.	
/W.W./	2	F. B. KLUGMAN et al., Effect of ketotifen on adriamycin toxicity: Role of histamine, Cancer Letters, 1998 39(2):145-152.	
/W.W./	3	BRIASOULIS E. et al., Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions, <i>Annals of Oncology</i> 2000 11(7):899.	
•			

CE		5.4	
Examiner	/Walter Webb/	Date	12/20/2007
Signature	71741101 770007	Considered	12/20/2001

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is unique citation designation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

O P & FER 1 7 2008

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	e for form 1449				Complete if Known
				Application Number	10/542,602 (PCT/CA2004/000033)
INFC	PRMATIC	on dis	CLOSURE	I.A. Filing Date	January 19, 2004
STA	TEMEN'	T BY A	PPLICANT	First Named Inventor	Stuart A. Berger
				Art Unit	Not yet assigned
	(Use as mar	ny sheets as	necessary)	Examiner Name	Not yet assigned ·
Sheet	1	of	2	Attorney Docket Number	10723-107

			U.S. PATENT	DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevan
Initials *	Cite No. ¹	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
	-A-	US-			
		US			
		US-	•		
		US-			
		US			,
		US-		1	
		US-			
· ·		US-			
		US-			
		US-			
	1	US-	···		
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-			
	1	US-			

		FOREIGN PA	TENT DOCU	MENTS		
Examiner Initials*	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
	No.1	1 Deta Applicant	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵	
-						
				·		
						

Examiner Signature	/Walter Webb/	Date Considered	12/20/2007

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 801.04. 'Senter Office that issued the document, by the two-tetter code (MPO Standard ST.3). 'For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document.' 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

S	ubstitute 1	for form 1449	В/РТО				Complete if Known
	NEO	384 A TI	0N B		OL OCUPE	Application Number	10/542,602 (PCT/CA2004/000033)
					CLOSURE	I.A. Filing Date	January 19, 2004
S	STAT	EMEN.	TBY	AF	PPLICANT	First Named Inventor	Stuart A. Berger
						Art Unit	Not yet assigned
		(Use as ma	ny sheet:	S 85	necessary)	Examiner Name	Not yet assigned
S	heet	2		of	2	Attorney Docket Number	10723-107

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/W.W./	1	RAMU and RAMU (1992); Reversal of multidrug resistance by phenothiazines and structurally related compounds; Cancer Chemotherapy and Phermacology, 30:165-173.	
-			
-			

////aiter ///enn/	Date Considered	12/20/2007
-------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.